Close Menu

financial results

For the three months ended Sept. 30, the firm had total revenues of $8.2 million compared to $7.7 million a year ago.

The sequencing company reported preliminary fourth quarter revenues of $27 million and said it currently has $318 million in cash and investments.

The firm is projecting COVID-19 testing revenues of $865 million in the recently completed quarter, including $685 million in Veritor immunoassay sales.

The company brought in $20.2 million during the quarter, driven by strong biopharma revenue, with orders increasing for both its core services and new liquid biopsy offering.

For full-year 2020, the company expects revenues of approximately $417 million, which would be up 25 percent from a year ago.

The company said that in Q4 it placed 70 net new ePlex analyzers and finished the year with a global installed base of 792 analyzers.

The company anticipates total revenues of $3.9 billion for 2020, including $1 billion from its COVID-19-related business.

The Seattle-based firm expects product and service revenues of $35.7 million in the fourth quarter and $111.4 million in Fiscal Year 2020.

The firm also said that it placed 35 Sequel II/IIe Systems in Q4 2020, bringing its total installed base to 203 as of the end of the year.

CareDx expects fourth quarter revenues of $58.4 million to $58.6 million, an increase of approximately 63 percent compared to $35.8 million in Q4 2019.


The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.